Global leader in formulation and film technology manufacture to establish commercial scale production capabilities for Accordion Pill Carbidopa\/Levodopa capsules in FDA compliant facility<\/p>\n\n\n\n
JERUSALEM (March 12, 2018) \u2013 Intec Pharma Ltd. (NASDAQ, TASE: NTEC) (\u201cIntec\u201d or the \u201cCompany\u201d) today announces that it has partnered with LTS Lohmann Therapie-Systeme AG (\u201cLTS\u201d) for the manufacture of the Company\u2019s lead product candidate, Accordion Pill\u2122 Carbidopa\/Levodopa (AP-CD\/LD) as a treatment for the severe symptoms in advanced Parkinson\u2019s Disease patients. Under the agreement, LTS will manufacture the AP-CD\/LD capsules using Intec\u2019s proprietary Accordion Pill production technology in LTS\u2019 manufacturing facility in Andernach, Germany upon the completion of assembly of the production line. Currently, Intec is producing the AP-CD\/LD capsules for its Phase 3 clinical trial at its existing manufacturing facility in Jerusalem and will work together with LTS to establish commercial scale production capabilities for AP-CD\/LD capsules.
LTS\u2019 Andernach facility is compliant with the U.S. Food and Drug Administration\u2019s current Good Manufacturing Practices (\u201ccGMP\u201d) requirements that assure the proper design, monitoring and control of manufacturing processes and facilities. Furthermore, LTS\u00b4 Andernach facility has successfully passed audits from all major global regulatory agencies including the European EMA, J-PMDA, KFDA, CFDA and ANVISA.
\u201cWe are particularly pleased to be partnering with LTS, a global leader in the commercial manufacture of formulation and film technologies for the pharmaceutical industry. This is a key achievement for Intec as we near completion of our pivotal Phase 3 ACCORDANCE clinical trial in advanced Parkinson\u2019s Disease patients and advance our pre-commercial strategies for AP-CD\/LD,\u201d said Jeffrey A. Meckler, Chief Executive Officer of Intec Pharma.\u201d<\/p>\n\n\n\n
Nadav Navon, Chief Operating Officer added \u201cBuilt on nearly ten years of research and development, our state-of-the art and proprietary manufacturing process for the Accordion Pill is in good hands with LTS and its team of experts at it cGMP facilities.\u201d<\/p>\n\n\n\n
\u201cLTS is highly committed to contribute to the innovative opportunities of the Accordion Pill technology for Carbidopa\/Levodopa (AP-CD\/LD). LTS\u00b4 well proven capabilities in the scale up and large volume manufacture meet INTEC\u00b4s requirements for a reliable supply conforming with most stringent quality requirements.\u201d commented Michael Hoffmann, Chief Technology and Operating Officer of LTS.<\/p>\n\n\n\n
In addition to securing commercial scale manufacturing for AP-CD\/LD, Intec has made other inroads advancing its pre-commercial strategy. In recent months, Intec has enhanced its leadership with a number of key hires and initiated an in-depth market access analysis of the potential for AP-CD\/LD in the Parkinson’s Disease market. Initial results of the market analysis indicate there is a substantial market for AP-CD\/LD to potentially serve hundreds of thousands of patients suffering with Parkinson’s Disease.<\/p>\n\n\n\n
About LTS Lohmann Therapie-Systeme AG
LTS is a leading pharmaceutical technology company that develops and manufactures innovative drug delivery systems such as Transdermal Patches (\u201cTTS\u201d) and Oral Thin Films (\u201cOTF\u201d) for the pharmaceutical industry. LTS\u00b4 commercial offering encompasses more than 20 marketed products and a diverse pipeline of more than 30 development projects targeting multiple disease indications. LTS\u2019s innovation pipeline contains both partner-funded as well as proprietary, LTS-funded projects. LTS maintains its leading position through the continuous refinement of its core TTS and OTF technologies and by advancing emerging drug delivery technologies, including Micro Array Patches for the transdermal delivery of large molecule, biological actives. Founded in 1984, LTS operates today from two sites in Andernach, Germany and West Caldwell, NJ, USA and a representation in Shanghai, China.
About Intec Pharma Ltd.
Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology. The Company’s Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing an efficient gastric retention and specific release mechanism. The Company’s product pipeline includes two product candidates in clinical trial stages: Accordion Pill Carbidopa\/Levodopa, or AP-CD\/LD, which is being developed for the treatment of Parkinson’s disease symptoms in advanced Parkinson’s disease patients, and AP-cannabinoids, an Accordion Pill to deliver either or both of the primary cannabinoids contained in Cannabis sativa, cannabidiol (CBD) and tetrahydrocannabinol (THC) for various indications including low back neuropathic pain and fibromyalgia.<\/p>\n\n\n\n
Contact:
Dr. Iris Schnitzler
Marketing and Market Services
iris.schnitzler@ltslohmann.de<\/p>\n","protected":false},"excerpt":{"rendered":"
Initial results of the market analysis indicate there is a substantial market for AP-CD\/LD to potentially serve hundreds of thousands of patients suffering with Parkinson’s Disease. <\/p>\n","protected":false},"author":3,"featured_media":9448,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[14],"tags":[],"class_list":["post-6281","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-press-releases"],"_links":{"self":[{"href":"https:\/\/ltslohmann.com\/en\/wp-json\/wp\/v2\/posts\/6281","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ltslohmann.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ltslohmann.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ltslohmann.com\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/ltslohmann.com\/en\/wp-json\/wp\/v2\/comments?post=6281"}],"version-history":[{"count":2,"href":"https:\/\/ltslohmann.com\/en\/wp-json\/wp\/v2\/posts\/6281\/revisions"}],"predecessor-version":[{"id":16442,"href":"https:\/\/ltslohmann.com\/en\/wp-json\/wp\/v2\/posts\/6281\/revisions\/16442"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ltslohmann.com\/en\/wp-json\/wp\/v2\/media\/9448"}],"wp:attachment":[{"href":"https:\/\/ltslohmann.com\/en\/wp-json\/wp\/v2\/media?parent=6281"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ltslohmann.com\/en\/wp-json\/wp\/v2\/categories?post=6281"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ltslohmann.com\/en\/wp-json\/wp\/v2\/tags?post=6281"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}